Xencor Q2 2024 Earnings Report $24.57 +0.44 (+1.82%) (As of 12/23/2024 05:45 PM ET) Earnings HistoryForecast Xencor EPS ResultsActual EPS-$1.07Consensus EPS -$0.82Beat/MissMissed by -$0.25One Year Ago EPS-$0.37Xencor Revenue ResultsActual Revenue$16.96 millionExpected Revenue$21.13 millionBeat/MissMissed by -$4.17 millionYoY Revenue Growth-62.70%Xencor Announcement DetailsQuarterQ2 2024Date8/5/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseXNCR Earnings HistoryPowered by Six Stocks That Could Soar on Trump’s First Day Back (Ad)The recent election results have clarified a path forward, creating opportunities that weren't as clear just months ago. Louis has identified six specific AI stocks that are poised to benefit from this.Click here to learn which AI companies Louis believes will dominate the market... Xencor Earnings HeadlinesBrokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $36.56December 18, 2024 | americanbankingnews.comXencor (NASDAQ:XNCR) Coverage Initiated by Analysts at Wells Fargo & CompanyDecember 15, 2024 | americanbankingnews.comSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just months ago. Louis has identified six specific AI stocks that are poised to benefit from this.December 24, 2024 | InvestorPlace (Ad)Xencor initiated with an Overweight at Wells FargoDecember 13, 2024 | markets.businessinsider.comXencor’s Promising Pipeline and Strategic Partnerships Drive Buy RatingDecember 13, 2024 | markets.businessinsider.comWells Fargo Initiates Coverage of Xencor (XNCR) with Overweight RecommendationDecember 13, 2024 | msn.comSee More Xencor Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xencor? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xencor and other key companies, straight to your email. Email Address About XencorXencor (NASDAQ:XNCR), a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.View Xencor ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
